Strategies aimed at reactivating exhausted MAIT cells, modulating MR1 antigen presentation, minimizing protumor MAIT cell subsets, and leveraging cytotoxic MAIT subsets or capabilities represent promising avenues for future cancer treatment. Here, MR1 is linked to cancer.